INTERNATIONAL PATENT: ELI LILLY AND COMPANY FILES APPLICATION FOR "ACTIVATION OF EGFR/HER2/3 IN CANCER AFTER TREATMENT WITH AN INHIBITOR OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3)"

GENEVA, Dec. 24 -- ELI LILLY AND COMPANY (Lilly Corporate CenterIndianapolis, Indiana 46285) filed a patent application (PCT/US2025/032418) for "ACTIVATION OF EGFR/HER2/3 IN CANCER AFTER TREATMENT WITH AN INHIBITOR OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3)" on Jun 05, 2025. With publication no. WO/2025/259519, the details related to the patent application was published on Dec 18, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): GOETZ, Eva Marie (c/o Eli Lilly and CompanyP.O. Box 6288Indianapolis, Indiana 46206-6288), EVANS, Robert John (c/o Eli Lilly and CompanyP.O. Box 6288Indianapolis,...